DOCSDoximity, Inc.

Price: $31.75 | Today's Change: -4.31%

---

What Happened

Doximity, Inc. filed an 8-K with the SEC on November 5, 2026 disclosing its second-quarter fiscal year 2027 financial results (Item 2.02 — Results of Operations and Financial Condition). The company reported revenue of $314,438,000, operating income of $118,198,000, and net income of $115,379,000 for the quarter. Diluted earnings per share came in at $0.57, with basic EPS of $0.61.

---

Why It Matters

The headline figures show Doximity maintaining a notably strong profit margin profile — operating income of roughly $118.2M on revenue of $314.4M implies an operating margin of approximately 37.6%, which is exceptional for a healthcare technology platform. Net income of $115.4M is closely in line with operating income, suggesting a relatively clean income statement with limited non-operating noise. For investors, the key practical takeaway is that Doximity continues to convert a large share of its top-line revenue directly into profit, reinforcing the financial durability of its physician-network business model. The stock's -4.31% move on the day of this report suggests the market may have had higher expectations than the results delivered, or that guidance or other commentary accompanying the release gave investors pause — though any forward-looking statements from management are outside the scope of this filing-based report.

---

Analysis

Doximity's Q2 FY2027 numbers confirm the company remains one of the more profitable businesses in health-tech, with a continued ability to generate meaningful operating leverage. The near-37.6% operating margin is a structural feature of Doximity's asset-light, software-driven model — it owns the network that pharmaceutical and health system advertisers rely on to reach physicians, and that network has high switching costs.

That said, the negative share-price reaction on the filing date is worth watching carefully. When a company posts strong absolute margins but the stock still sells off materially, it typically reflects one or more of the following: revenue growth expectations that the reported figures didn't match, forward guidance that disappointed, or broader market conditions applying pressure on high-multiple software names. Investors following this company should focus on:

• Revenue trajectory: Whether $314.4M represents acceleration or deceleration relative to prior quarters.
• Operating margin sustainability: Whether the ~37.6% level is repeatable or benefited from one-time cost efficiencies.
• Management commentary: Any guidance on pharmaceutical advertising spending, Doximity's largest revenue driver.

This follows StockWatch's existing initiating coverage of Doximity. The structured facts from this filing add a fresh data point to that analytical foundation.

---

Disclaimer

This report is a news and informational summary based solely on data extracted from Doximity's SEC filing dated November 5, 2026, and is provided for informational purposes only. It does not constitute investment advice, a recommendation to buy or sell any security, or a research rating of any kind. Investors should conduct their own due diligence and consult a qualified financial professional before making any investment decision.

Existing Coverage

StockWatch has full coverage on DOCS, published 2026-09-08. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-05. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1516513/000151651326000049/docs-20261105.htm